89BIO (ETNB)
(Delayed Data from NSDQ)
$8.58 USD
-0.34 (-3.81%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $8.63 +0.05 (0.58%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ETNB 8.58 -0.34(-3.81%)
Will ETNB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ETNB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ETNB
Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
ETNB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
89BIO (ETNB) Just Overtook the 200-Day Moving Average
89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average
Other News for ETNB
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
3 Potential Biopharma Buyout Targets
89bio assumed with a Buy at BofA
Hepion ends Phase 2 study for NASH drug due to cash restraints
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors